GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (OTCPK:TEVJF) » Definitions » Price-to-Owner-Earnings

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Price-to-Owner-Earnings

: (As of Today)
View and export this data going back to . Start your Free Trial

As of today (2024-04-17), Teva Pharmaceutical Industries's share price is $11.98. Teva Pharmaceutical Industries does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Teva Pharmaceutical Industries's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Teva Pharmaceutical Industries was 42.32. The lowest was 9.30. And the median was 15.86.


TEVJF's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 26.975
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-17), Teva Pharmaceutical Industries's share price is $11.98. Teva Pharmaceutical Industries's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.47. Therefore, Teva Pharmaceutical Industries's PE Ratio for today is At Loss.

As of today (2024-04-17), Teva Pharmaceutical Industries's share price is $11.98. Teva Pharmaceutical Industries's EPS without NRI for the trailing twelve months (TTM) ended in was $2.56. Therefore, Teva Pharmaceutical Industries's PE Ratio without NRI for today is 4.68.

During the past 13 years, Teva Pharmaceutical Industries's highest PE Ratio without NRI was 13.32. The lowest was 1.34. And the median was 4.37.


Teva Pharmaceutical Industries Price-to-Owner-Earnings Historical Data

The historical data trend for Teva Pharmaceutical Industries's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Teva Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries Price-to-Owner-Earnings Distribution

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Price-to-Owner-Earnings falls into.



Teva Pharmaceutical Industries Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Teva Pharmaceutical Industries's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=11.98/-0.20
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Teva Pharmaceutical Industries  (OTCPK:TEVJF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Teva Pharmaceutical Industries Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description

Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Headlines

From GuruFocus

Teva Reports Second Quarter 2023 Financial Results

By Business Wire 08-02-2023

Teva Announces Changes to Executive Management Team

By Business Wire 09-28-2023